Metachromatic leukodystrophy: An overview of current and prospective treatments

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Biffi, A ^a   Lucchini, G ^b   Rovelli, A ^b   Sessa, M ^a,c  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLSULFATASE; COMPLEMENTARY DNA; RECOMBINANT ARYLSULFATASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; BLOOD CHEMISTRY; CELL BASED GENE THERAPY; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DNA MODIFICATION; ENZYME REPLACEMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METACHROMATIC LEUKODYSTROPHY; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

BLOOD-BRAIN BARRIER; CEREBROSIDE-SULFATASE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GENE THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKODYSTROPHY, METACHROMATIC; RECOMBINANT PROTEINS; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 55749107302     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.275     Document Type: Review

References (45)

1. Vellodi A. Lysosomal storage disorders. Br J Haematol 2004; 128 413-431.
2. Beck M. New therapeutic options for lysosomal storage disorders: Enzyme replacement, small molecules and gene therapy. Hum Genet 2007; 121: 1-22.
3. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229-239.
4. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone marrow Transplant 2003; 31: 1105-1117.
5. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350: 1960-1969.
6. Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G et al. Outcomes of haematopietic cell transplantation for MPS-I in Europe: A risk factor analysis for graft-failure. Bone Marrow Transplant 2007; 40: 225-233.
7. Orchard PJ, Blazar BR, Wagner J, Charnas L, Krivit W, Tolar J. Hematopoietic cell therapy for metabolic disease. J Pediatr 2007; 151: 340-346.
8. Boeleens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis 2006; 29: 413-420.
9. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008; 41: 99-108.
10. Rovelli AM. The controversial and changing role of haematopoietic cell transplantation far lysosomal storage disorders: An update. Bone Marrow Transplant 2008; 41 (Suppl 2): S87-S89.
11. Sevin C, Aubourg P, Cartier N. Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J Inherit Metab Dis 2007; 30: 175-183.
12. Biffi A, Naldini L. Novel candidate disease for gene therapy: metachromatic leukodystrophy. Expert Opin Biol Ther 2007; 7: 1193-1205.
13. Von Figura K, Jaeken J. Metachromatic Leukodystrophy. In: Scriver CR, Valle D, Sly WS (eds). The Metabolic and Molecular Bases of Inherited Diseases. Mac Graw-Hill: New York, NY, 2001, pp 3695-3724.
14. Aicardi J (ed). Disease of the Nervous System in Childhood, 2nd edn. Cambridge University Press: Cambridge, 1998, 907 pp.
15. Holtschmidt H, Sandhoff K, Kwon HJ, Harzer K, Nakano T, Suzuki K. Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem 1991; 266: 7556-7560.
16. Polten A, Fluharty AL, Fluharty CB, Kappler J, Von Figura K, Gieselmann V. Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 1991; 324: 424-425.
17. Gieselmann V, Polten A, Kreysing J, Kappler J, Fluharty A, Von Figura K. Molecular genetics of metachromatic leukodystrophy. Dev Neurosc 1991; 13: 222-227.
18. Berger J, Loschl B, Bernheimer H, Lugowska A, Tylki-Szymanska A, Gieselmann V et al. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Genet 1997; 69: 335-340.
19. Regis S, Filocamo M, Stroppiano M, Corsolini F, Gatti R. Molecular analysis of the ary1sulphatase A gene in late infantile metachromatic leucodystrophy patients and healthy subjects from Italy. J Med Genet 1996; 33: 251-252.
20. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, De Jong JG, Van Weely S et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105: 151-156.
21. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004; 12: 87-92.
22. Baum H, Dodgson KS, Spencer B. The assay of arylsulpahatases A and B. Clin Chim Acta 1950; 4: 453-460.
23. Coulter-Mackie M, Gagnier L. Two new polymorphisms in the arylsulfatase A gene and their haplotype associations with normal, metachromatic leukodystrophy and pseudodeficiency alleles. Am J Med Genet 1997; 73: 32-35.
24. Tylki-Szymanska AT, Lugowska A. Practical suggestions in diagnosing metachromatic leukodystrophy in probands and in testing family members. Europ Neurology 1998; 40: 67-70.
25. Eng B, Nakamura LN, O'Reilly N, Schokman N, Nowaczyk MM, Krivit W et al. Identification of nine novel arylsulfatase A (ARSA) gene mutations in patients with metachromatic leukodystrophy (MLD). Hum Mutat 2003; 22: 418-419.
26. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992; 49: 401-406.
27. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immun 2004; 26: 119-132.
28. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995; 345: 1398-1402.
29. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18: 413-429.
30. Görg M, Wilck W, Granitzny B, Suerken A, Lukaes Z, Ding X et al. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: A 13-year follow-up. J Child Neurol 2007; 22: 1139-1142.
31. Meuleman N, Vanhaelen G, Tondreau T, Lewalle P, Kwan J, Bennati J et al. Reduced intensità conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: A case report. Haematologica 2008; 93: E11-e13.
32. Solders G, Celsing G, Hagenfeldt L, Ljungman P, Iberg B, Ringden O. Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy. Bone Marrow Transplant 1998; 22: 1119-1122.
33. Kapaun P, Dittmann RW, Granitzny B, Eickhoff W, Wulbrand H, Neumaier-Probst E et al. Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation. J Child Neurol 1999; 14: 222-228.
34. Kidd D, Nelson J, Jones F, Dusoir H, Wallace I, McKinstry S et al. Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch Neurol 1998; 55: 98-99.
35. Navarro C, Fernández JM, Domínguez C, Fachal C, Alvarez M. Late juvenile metachromatic leukodystrophy treated with bone marrow transplantation; a 4-year follow-up study. Neurology 1996; 46 254-256.
36. Malm G, Ringdén O, Winiarski J, Gröndahl E, Uyebrant P, Eriksson U et al. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1003-1008.
37. Escolar ML, Poe M, Provenzale JM, Richards KC, Allison J, Wood S et al. Transplantation of umbilical cord-blood in babies with infantile Krabbe's disease, New Engl J Med 2005; 352: 2069-2081.
38. Martin HP, Poe MD, Szabolcs P, Martin P, Subag P, Vinod P et al. Neurodevelopmental outcomes of unrelated umbilical cord transplantation for metachromatic leukodystrophy. Biol Blood Marrow Transplant 2007; 13(Suppl S): 63, abstract 168.
39. Bredius RGM, Laan LAEM, Lankester AC, Poorthuis BJHM, van Tol MJD, Egeler RM et al. Early marrow transplantation in a pre-symptomatic neonate with late-infantile metachromatic leukodystrophy does not halt disease progression. Bone Marrow Transplant 2007; 39: 309-310.
40. Matzner U, Herbst E, Hedayati KK, Lüllmann-Rauch R, Wessig C, Schröder S et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005; 14: 1139-1152.
41. Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest 2004; 113: 1118-1129.
42. Biffi A, Capotondo A, Fasano S, Del Carro U, Marchesini S, Azuma H et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006; 116: 3070-3082.
43. Guenechea G, Gan OI, Inamitsu T, Dorrell C, Pereira DS, Kelly M et al. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther 2000; 1: 566-573.
44. Capotondo A, Cesani M, Pepe S, Fasano S, Gregori S, Tononi L et al. Over-expression of arylsulfatase A in target cells is safe and enables efficacious gene therapy of metachromatic leukodystrophy. Hum Gene Ther 2007; 18: 821-836.
45. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.